Cybereason is the leader in endpoint protection, offering endpoint detection and response, next-generation antivirus, managed monitoring and IR services. Founded by elite intelligence professionals born and bred in offense-first hunting, Cybereason gives enterprises the upper hand over cyber adversaries. The Cybereason platform is powered by a custom-built in-memory graph, the only truly automated hunting engine anywhere. It detects behavioral patterns across every endpoint and surfaces malicious operations in an exceptionally user-friendly interface. Cybereason is privately held and headquartered in Boston with offices in London, Tel Aviv, and Tokyo.

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.